AstraZeneca
NEWS
The company said its combination treatment of Imfinzi (durvalumab) plus tremelimumab, an anti-CTLA4 antibody and Imfinzi on its own, did not improve overall survival in patients with this advanced form of bladder cancer.
AstraZeneca says the overrun is because of the complexity of the construction, inflation and other factors.
Under the license deal, RedHill is paying AstraZeneca $52.5 million up front with another non-contingent payment of $15 million 18 months after the deal closes.
The most recent BioSpace Ideal Employer Report revealed the impact of team dynamics on employees within life sciences organizations.
The BioSpace Ideal Employer Report examined aspects regarding the importance of culture within life sciences organizations.
It was another busy week for clinical trial updates. Here’s a look.
Incidence rates for liver cancer began rising in the mid-1970s, and they are expected to go up through at least 2030. This report aims to give an overview of liver cancer, as well as explore current therapies, drugs in the pipeline and the future treatment landscape for patients and their caregivers living with liver cancer.
In addition to various deal news, AstraZeneca had clinical trial news today as well.
That would accelerate the company’s “decarbonization” plan by more than a decade.
JOBS
IN THE PRESS